Linustedastatum

Linustedastatum (Linustedastat; FOR-6219) is an orally active hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1) inhibitor. Linustedastatum can be used for the study of endometriosis[1][2].

Product Specifications

CAS Number

[2254299-48-2]

Product Name Alternative

Linustedastat; FOR-6219; OG-6219

UNSPSC

12352005

Target

17β-HSD

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/linustedastatum.html

Purity

98.10

Solubility

DMSO : ≥ 170 mg/mL

Smiles

C[C@@]12[C@]([C@@H](C/C2=N\O)CCC(NC3=CC=C(C=N3)F)=O)([H])[C@@]4([H])[C@@](CC1)([H])C5=CC=CC(F)=C5CC4

Molecular Formula

C26H29F2N3O2

Molecular Weight

453.52

References & Citations

[1]Linustedastatum (Linustedastat) . WHO Drug Information, Vol. 37, No. 4, 2023.|[2]Barra F, et al. Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis. Expert Opin Investig Drugs. 2019 Jun;28 (6) :501-504.